CNS Drugs

CNS drug development faces unique challenges yet has produced multiple recent breakthroughs. The session covers lecanemab (Leqembi) and donanemab in Alzheimer's, KarXT (Cobenfy) for schizophrenia as first M1/M4 muscarinic agonist, psilocybin in depression (Compass COMP360), BTK inhibitors in MS (tolebrutinib, fenebrutinib), anti-CGRP migraine therapy class, and the post-SSRI psychiatric pipeline. Discussion addresses zuranolone (Zurzuvae) for postpartum depression, AXS-05 for depression, orexin-receptor agonists in narcolepsy and insomnia, GLP-1 effects on CNS (Alzheimer's prevention trials), and the regulatory pathway for psychedelic-assisted therapy.